The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors.
Breton, R., Housset, D., Mazza, C., Fontecilla-Camps, J.C.(1996) Structure 4: 905-915
- PubMed: 8805577 
- DOI: https://doi.org/10.1016/s0969-2126(96)00098-6
- Primary Citation of Related Structures:  
1FDS, 1FDT - PubMed Abstract: 
The steroid hormone 17beta-estradiol is important in the genesis and development of human breast cancer. Its intracellular concentration is regulated by 17beta-hydroxysteroid dehydrogenase, which catalyzes the reversible reduction of estrone to 17beta-estradiol. This enzyme is thus an important target for inhibitor design. The precise localization and orientation of the substrate and cofactor in the active site is of paramount importance for the design of such inhibitors, and for an understanding of the catalytic mechanism.
Organizational Affiliation: 
Laboratoire de Cristallographie et Cristallogenése des Protéines, Institut de Biologie Structurale J.-P. Ebel, CEA - CNRS 41, avenue des Martyrs, F-38027 Grenoble cedex, France.